Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "Stemline Therapeutics, Inc." (STML) Report Updated: Oct 15, 2017 | Print This Page

Get more stock ratings by Louis Navellier

"Stemline Therapeutics, Inc." (STML)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Biotechnology

Stock Analysis

Rating: Monthly View

October November December January February March April May June July August September

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up downgrade
service keys

"Stemline Therapeutics, Inc."© quotemedia

Company Profile

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary therapeutics for cancer stem cells and bulk tumors in the United States. It develops SL-401, a clinically active targeted therapy directed to the interleukin-3 receptor, which has completed Phase I/II clinical trials for advanced hematologic cancers; and SL-701, an immunotherapy to attack tumors that has completed Phase I/II clinical trials. The company’s preclinical candidates include SL-801, a novel oral small molecule reversible inhibitor of nuclear transport for the treatment of solid and hematologic cancers; and SL-501, a next-generation IL-3R-targeted therapy for the treatment of various autoimmune diseases. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.